Cargando…

ELF3 Is a Target That Promotes Therapeutic Efficiency in EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer Cells via Inhibiting PKCί

(1) Background: Mutations in epidermal growth factor receptor (EGFR) proteins account for many non-small cell lung cancers (NSCLCs), and EGFR tyrosine kinase inhibitors (TKIs) are being used as targeted therapeutics. However, resistance to TKIs continues to increase owing to additional mutations in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Jeon-Soo, Choi, Young Eun, Kim, Sunshin, Han, Ji-Youn, Goh, Sung-Ho
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8620479/ https://www.ncbi.nlm.nih.gov/pubmed/34830169 http://dx.doi.org/10.3390/ijms222212287

Ejemplares similares

Coordination of glioblastoma cell motility by PKCι
por: Baldwin, R Mitchell, et al.
Publicado: (2010)

Oncogenic PKC-ι activates Vimentin during epithelial-mesenchymal transition in melanoma; a study based on PKC-ι and PKC-ζ specific inhibitors
por: Ratnayake, Wishrawana S., et al.
Publicado: (2018)

Targeting PKCι-PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinoma
por: Ito, Masaoki, et al.
Publicado: (2019)

PKCι and YAP1 are crucial in promoting pancreatic tumorigenesis
por: Wang, Peipei, et al.
Publicado: (2018)

Clinical significance of atypical protein kinase C (PKCι and PKCζ) and its relationship with yes-associated protein in lung adenocarcinoma
por: Kim, Kyung-Hee, et al.
Publicado: (2019)

PKCι depletion initiates mitotic slippage-induced senescence in glioblastoma
por: Restall, Ian J, et al.
Publicado: (2015)

Investigating pathogenic SNP of PKCι in HCV-induced hepatocellular carcinoma
por: Khan, Naila, et al.
Publicado: (2023)

Early On-Treatment Prediction of the Mechanisms of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors
por: Choi, Yu-ra, et al.
Publicado: (2022)

Control of atypical PKCι membrane dissociation by tyrosine phosphorylation within a PB1-C1 interdomain interface
por: Cobbaut, Mathias, et al.
Publicado: (2023)

PKCι regulates nuclear YAP1 localization and ovarian cancer tumorigenesis
por: Wang, Yin, et al.
Publicado: (2016)

Atypical protein kinase C iota (PKCλ/ι) ensures mammalian development by establishing the maternal–fetal exchange interface
por: Bhattacharya, Bhaswati, et al.
Publicado: (2020)

The aPKCι blocking agent ATM negatively regulates EMT and invasion of hepatocellular carcinoma
por: Ma, C Q, et al.
Publicado: (2014)

Lack of an association between the aPKCλ/ι expression in prostate cancer and the patient outcomes
por: Yokomizo, Yumiko, et al.
Publicado: (2017)

PKCλ/ι signaling—a common node for normal cellular development and breast oncogenesis
por: Paul, Arindam, et al.
Publicado: (2015)

Effects of Atypical Protein Kinase C Inhibitor (DNDA) on Lung Cancer Proliferation and Migration by PKC-ι/FAK Ubiquitination Through the Cbl-b Pathway
por: BommaReddy, Raja Reddy, et al.
Publicado: (2020)

Ect2 links the PKCι-Par6α Complex to Rac1 Activation and Cellular Transformation
por: Justilien, Verline, et al.
Publicado: (2009)

PKCι interacts with Rab14 and modulates epithelial barrier function through regulation of claudin-2 levels
por: Lu, Ruifeng, et al.
Publicado: (2015)

The Rho family GEF FARP2 is activated by aPKCι to control tight junction formation and polarity
por: Elbediwy, Ahmed, et al.
Publicado: (2019)

Conditional knockout of polarity complex (atypical) PKCι reveals an anti-inflammatory function mediated by NF-κB
por: Forteza, Radia, et al.
Publicado: (2016)

aPKCι promotes gallbladder cancer tumorigenesis and gemcitabine resistance by competing with Nrf2 for binding to Keap1
por: Tian, Li, et al.
Publicado: (2019)

Deficiency of PKCλ/ι alleviates the liver pathologic impairment of Schistosoma japonicum infection by thwarting Th2 response
por: Mei, Congjin, et al.
Publicado: (2022)

Compartmentalisation of EGFR signalling might potentiate the optimal use of EGFR tyrosine kinase inhibitors in cancer therapeutics
por: Karamouzis, M V, et al.
Publicado: (2007)

Downregulation of ASPP2 promotes gallbladder cancer metastasis and macrophage recruitment via aPKC-ι/GLI1 pathway
por: Tian, Li, et al.
Publicado: (2018)

Protein kinase C(ι) and SRC signaling define reciprocally related subgroups of glioblastoma with distinct therapeutic vulnerabilities
por: Kenchappa, Rajappa S., et al.
Publicado: (2021)

The ΙgΕ-epitome viewed through the eyes of human monoclonal ΙgΕ
por: Levin, Mattias, et al.
Publicado: (2014)

Kinase-Inactivated EGFR Is Required for the Survival of Wild-Type EGFR-Expressing Cancer Cells Treated with Tyrosine Kinase Inhibitors
por: Thomas, Rintu, et al.
Publicado: (2019)

Mechanisms of resistance to EGFR tyrosine kinase inhibitors
por: Huang, Lihua, et al.
Publicado: (2015)

Protein kinase Cι is required for Ras transformation and colon carcinogenesis in vivo
por: Murray, Nicole R., et al.
Publicado: (2004)

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
por: Xu, Haiyuan, et al.
Publicado: (2019)

Effect of Combining EGFR Tyrosine Kinase Inhibitors and Cytotoxic Agents on Cholangiocarcinoma Cells
por: Boonsri, Boonyakorn, et al.
Publicado: (2021)

Microwave ablation with continued EGFR tyrosine kinase inhibitor therapy prolongs disease control in non‐small‐cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors
por: Li, Xin, et al.
Publicado: (2018)

Imaging of EGFR and EGFR Tyrosine Kinase Overexpression in Tumors by Nuclear Medicine Modalities
por: Mishani, Eyal, et al.
Publicado: (2008)

Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma
por: Makhlin, Igor, et al.
Publicado: (2019)

Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with EGFR Mutations
por: Suda, Kenichi, et al.
Publicado: (2021)

Structural Insight and Development of EGFR Tyrosine Kinase Inhibitors
por: Amelia, Tasia, et al.
Publicado: (2022)

aPKC: the Kinase that Phosphorylates Cell Polarity
por: Hong, Yang
Publicado: (2018)

Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer
por: Ji, Wonjun, et al.
Publicado: (2013)

Different mutational characteristics of the subsets of EGFR-tyrosine kinase inhibitor sensitizing mutation-positive lung adenocarcinoma
por: Kim, Eun Young, et al.
Publicado: (2018)

Transcription co-activator P300 activates Elk1-aPKC-ι signaling mediated epithelial-to-mesenchymal transition and malignancy in hepatocellular carcinoma
por: Ma, Chaoqun, et al.
Publicado: (2020)

ELFE at CERN
por: Burkhardt, H
Publicado: (1999)

Cannot write session to /tmp/vufind_sessions/sess_e6itiu5eafbs7f9edg4ldeabcu